Sponsored by:
Facebook (FB)
JP Morgan (JPM)
AutoZone (AZO)
Yahoo (YHOO)
Focus Stocks
Featured Stories
Medtronic Reports Fourth Quarter Earnings
Cracker Barrel Reports Earnings, Increases Guidance
Best ETFs For Facebook Exposure
Is Yum! Brands Closing in to Support?
Intuitive Surgical Bullish Signs
Research Analyst's Up/Downgrades ( ZMH, SYK, STJ, BSX, GRMN, ONNN, AAP, RSH, KBH, LEN )
Published on Thursday, 19 January 2012 09:04 Written by Danny Miller
New York, January 19th (TradersHuddle.com) - Research Analyst's early calls ahead of the bell.
Zimmer Holdings (NYSE:ZMH) was downgraded to Market Perform from Outperform at Bernstein.
Stryker (NYSE:SYK) was downgraded to Market Perform from Outperform at Bernstein.
St. Jude Medical (NYSE:STJ) was upgraded to Outperform at Bernstein.
Boston Scientific (NYSE:BSX) upgraded to Outperform at Bernstein.
Garmin (NASDAQ:GRMN) was upgraded to a Buy from Hold at Canaccord Genuity.
ON Semiconductor (NASDAQ:ONNN) was upgraded to a Buy from Neutral at UBS.
Advance Auto Parts (NYSE:AAP) was upgraded to Outperform from Neutral at Credit Suisse.
RadioShack (NYSE:RSH) was downgraded to Underperform from Neutral at Credit Suisse.
KB Home (NYSE:KBH) was downgraded to a Sell from Neutral at UBS.
Lennar (NYSE:LEN) was downgraded to a Neutral from Buy at UBS.
Related Articles
- Trading Idea: Entry Levels for Boston Scientific
- Stryker Is Between the 50 and 200 Day Moving Averages
- Close to the 200 Day Moving Average: Stryker
- Bears Appeared on Boston Scientific
- Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
- PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
- Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
- Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR
- Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure
- One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
Related Partner Headlines
- St Jude Medical Inc. (STJ): Today's Featured Health Services Loser - TheStreet.com
- Boston Scientific: PROMUS Element Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study - Benzinga
- Boston Scientific Announces FDA Approval and U.S. Launch of EPIC Vascular Stent - Benzinga
- Boston Scientific Announces Positive Data from Lotus Transcatheter Aortic Valve Trial - Benzinga
- Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial - Benzinga
- FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings - Benzinga
- UPDATE: Citigroup Reiterates Sell Rating, Lowers PT for St. Jude Medical - Benzinga
- UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Boston Scientific - Benzinga
- UPDATE: Goldman Sachs Upgrades St. Jude Medical; Raises PT - Benzinga
- St. Jude Medical Announces Results of SCD-HeFT 10-Year Follow-up Study; Confirms ICD Therapy Improves Long-Term Survival of Patients with Heart Failure - Benzinga
What’s the next under-$10 stock that could be ready to skyrocket? Find out now when you join David Peltier at Stocks Under $10.
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
